AtriCure, established in 2000, is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Its patented Isolator bipolar ablation system is a standard treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation. AtriCure has received clearance from the Food and Drug Administration to ablate soft tissue during surgical procedures. AtriCure has headquarters in West Chester, Ohio, and is traded on the NASDAQ under the symbol ATRC.